- Conditions
- Drug Interaction Potential
- Interventions
- Tolbutamide, Midazolam, Pexidartinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
- Interventions
- Canakinumab 150 mg, Placebo to Canakinumab
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
- Conditions
- Adult Solid Neoplasm
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Healthy Volunteers
- Interventions
- Ritlecitinib, Tolbutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, Tolbutamide Inhibition - Tolbutamide & Fluconazole
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hepatitis C, Chronic
- Interventions
- midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more
- Conditions
- Drug Interactions
- Interventions
- Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Healthy Volunteers
- Interventions
- CT1812, tolbutamide, dextromethorphan, Omeprazole, midazolam
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Food-drug Interaction
- Interventions
- Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg
- Dietary Supplement · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 40 Years to 79 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Drug-drug Interaction
- Interventions
- tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas